The FOURIER study: The profound study of Nature is the most fertile source of discovery
Open Access
- 1 March 2017
- journal article
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 58 (2) , 146-147
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Cardiovascular Efficacy and Safety of Bococizumab in High-Risk PatientsNew England Journal of Medicine, 2017
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsJAMA, 2016
- European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular riskEuropean Heart Journal, 2016
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysisAtherosclerosis, 2016
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasEuropean Heart Journal, 2016
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trialAmerican Heart Journal, 2014
- The biology and therapeutic targeting of the proprotein convertasesNature Reviews Drug Discovery, 2012
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010